Viventia Bio, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Viventia Bio, Inc. | VITA - NASDAQ |
TBD |
$0.00 |
$0.00 | TBD | |
Leerink Securites, Cowen and Company, Guggenheim Securities |
Co-Manager(s): |
Health Care |
Filing(s): FIled 2015-10-21
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Viventia Bio, Inc., and our comprehensive analysis, click "Buy Market Research".
About Viventia Bio, Inc. (adapted from Viventia Bio, Inc. prospectus):
They are a biologics oncology company focused on designing, engineering and developing targeted protein therapeutics, or TPTs. Our most advanced product candidates, Vicinium and Proxinium, are locally-administered TPTs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "VITA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved